Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Mar 2014 Status changed from not yet recruiting to withdrawn prior to recruitment, as per ClinicalTrials.gov record.
- 21 May 2013 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov.
- 25 Jul 2012 New trial record